Rescuing AAV gene transfer from antibody neutralization with an IgG-degrading enzyme
Asokan, A.; Elmore, Z.; Simon, K.; Oh, D.; Fanous, M.
Show abstract
Pre-existing humoral immunity to recombinant adeno-associated viral (AAV) vectors restricts the treatable patient population and efficacy of human gene therapies. Approaches to clear neutralizing antibodies (NAbs), such as plasmapheresis and immunosuppression are either ineffective or cause undesirable side effects. Here, we describe a clinically relevant strategy to rapidly and transiently degrade NAbs prior to AAV administration using an IgG degrading enzyme (IdeZ). We demonstrate that recombinant IdeZ efficiently cleaves IgG in dog, monkey and human antisera. Prophylactically administered IdeZ cleaves circulating, human IgG in mice and prevents AAV neutralization in vivo. In macaques, a single intravenous dose of IdeZ rescues AAV transduction by transiently reversing seropositivity. Importantly, IdeZ efficiently cleaves NAbs and rescues AAV transduction in mice passively immunized with individual human donor sera representing a diverse population. Our antibody clearance approach presents a new paradigm for expanding the prospective patient cohort and improving efficacy of AAV gene therapy.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Evolving Membrane-Associated Accessory Protein Variants for Improved Adeno-Associated Virus Production 95%
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 94%
- Administration of barcoded AAV capsid library to the putamen of non-human primates identifies variants with efficient retrograde transport 94%
Similar papers in this journal
- Small Alphaherpesvirus Latency-Associated Promoters Drive Efficient And Long-Term Transgene Expression In The Central Nervous System 94%
- Efficient Gene Transduction in Pigs and Macaques with the Engineered AAV Vector AAV.GT5 for Hemophilia B Gene Therapy 94%
- Screening of Chimeric GAA Variants in a Preclinical Study of Pompe Disease Results in Candidate Vector for Hematopoietic Stem Cell Gene Therapy 94%
Similar papers in this journal
- Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination 93%
- Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2 93%
- Replication-driven HBV cccDNA loss in chimeric mice with humanized livers 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.